Safety and Efficacy of Perampanel in Advanced Parkinson's Disease: A Randomized, Placebo-Controlled Study

Abstract

Perampanel, a novel, noncompetitive, selective AMPA-receptor antagonist was well tolerated and safe, but failed to achieve statistical significance in primary and secondary endpoints, in 263 patients with advanced Parkinson's disease

Keywords

• Parkinson's disease
• motor fluctuations
• dyskinesia
• perampanel
• AMPA receptor antagonist